PROMETRIKA is proud to work with many companies that focus on developing treatments for rare diseases, defined by the FDA as a condition afflicting fewer than 200,000 patients. Rare diseases impact over 30 million people in the U.S. today, 50% of whom are children. Our role ranges from full-service partner to preferred provider of specific functional services. We are a leading CRO with specialized expertise in more than 35 rare diseases, including:

  • 15q Duplication Syndrome
  • Acute lymphoblastic leukemia (ALL)
  • Acute myelodysplastic leukemia (MDS)
  • Acute myeloid leukemia (AML)
  • Alport Syndrome
  • Angelman syndrome
  • Arginase deficiency
  • Autosomal Dominant Polycystic Kidney Disease
  • Batten Disease
  • Duchenne Muscular Dystrophy
  • Fabry disease
  • Farber’s disease
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Fragile X Syndrome
  • Frontotemporal Degeneration (FTD)
  • Gaucher Type 1
  • Hereditary Angioedema (HAE)
  • Hunter Syndrome (Mucopolysaccharidosis II, MPS II)
  • Huntington’s disease
  • IgAN
  • Lupus
  • Methylmalonic Acidemia
  • Mucopolysaccharidosis I (MPS I)
  • Niemann-Pick disease
  • Neuroblastoma
  • Neuromyelitis Optica Spectrum Disorder (NMO)
  • Non-alcoholic steatohepatitis (NASH)
  • Pearson Syndrome
  • Pheochromocytoma and Paraganglioma
  • Pompe Disease
  • Propionic Acidemia
  • Sandhoff Disease
  • Sanfilippo syndrome (Mucopolysaccharidosis III, MPS-III)
  • Sarcoma
  • Sickle Cell Disease
  • Tay-Sachs Disease

Rare disease clinical trials pose several unique challenges:

  • Small patient populations impact recruitment rates and result in longer development timelines
  • Highly-heterogeneous collection of symptoms with variable phenotypes that can affect patients differently and make it difficult to define endpoints
  • Rare diseases are generally not well-understood and there is a dearth of natural history data needed for study design
  • Most are serious or life-threatening, and most patients have uniquely-specific unmet medical needs
  • There are few disease-specific outcome assessment tools available
  • Many rare diseases affect children, which introduces additional ethical and operational considerations
  • Researchers and patients are often geographically dispersed
  • Patient retention is more difficult due to issues like longer travel distances imposing greater burdens on patients and families

Benefits of Working with a CRO Experienced in Rare Disease Clinical Trials

With such a large number of rare diseases, each exhibiting a unique set of symptoms and challenges, CROs involved in clinical trials cannot rely on disease-specific knowledge alone. They must excel in problem solving and provide world-class customer service. PROMETRIKA’s model of project teams led by seasoned experts, along with its focus on flexibility and attentiveness, provides the perfect fit for clinical development of rare disease programs.

Our expertise working under challenging research conditions helps us achieve exceptional outcomes. We are well-versed in consulting with advocacy groups in order to develop patient-centric strategies, devising statistical methodologies to accommodate low sample sizes, and combining knowledge from natural history studies with data from clinical trials. PROMETRIKA’s experience in over 70 rare disease studies, as well as the cohesion of team members that have collaborated on clinical trials for decades, puts us in a perfect position to help make your rare disease development program a success.